Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we’ll get caught up with highlights from the annual meeting of The European Society for Medical Oncology, which has been underway in Berlin. We’re seeing the onward march of ADCs into earlier cancers, particularly breast.
Unexpected regulatory updates from Replimune, Summit Therapeutics
From STAT’s Adam Feuerstein: Let’s start with Replimune, which said this morning the Food and Drug Administration will review RP1, its therapy for advanced melanoma, for a second time, based on a resubmission that included additional data and analysis from a completed clinical trial. The new approval decision date is April 10.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply